Literature DB >> 16434368

Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease.

Theodoros P Vassilakopoulos1, Maria K Angelopoulou, Marina P Siakantaris, Nikos Konstantinou, Argyrios Symeonidis, Themistoklis Karmiris, Panayiotis Repoussis, Paraskevi Roussou, Athanassios Meletios Dimopoulos, Styliani I Kokoris, Evangelia M Dimitriadou, Marie-Christine Kyrtsonis, Maria N Dimopoulou, Constantinos Tsatalas, Garyfallia Kokkinis, Effimia Vrakidou, Vassiliki Grigoraki, Christos Poziopoulos, Marina Stamatellou, Dimitra Liapis, George Georgiou, Panayiotis Panayiotidis, Gerassimos A Pangalis.   

Abstract

BACKGROUND AND OBJECTIVES: Pure infradiaphragmatic Hodgkin's lymphoma (HL) is a rare disease. The prognostic impact of a purely infradiaphragmatic localization of this lymphoma is controversial. We aimed to evaluate the baseline clinicopathologic features, prognostic factors and outcome of a large series of consecutive patients with pure infradiaphragmatic HL. DESIGN AND METHODS: We analyzed 131 patients with clinical stage I/II infradiaphragmatic HL treated with ABVD or equivalent regimens with or without radiotherapy, and compared 54 of them with 444 patients with pure supradiaphragmatic disease, who were treated at the same center.
RESULTS: Older age, clinical stage II (borderline), involvement of > or =3 sites, lymphocyte predominant histology, elevated serum beta2-microglobulin and higher International Prognostic Score were more frequent in patients with infradiaphragmatic disease than in those with supradiaphragmatic disease, while nodular sclerosis was less frequent. The complete remission rate was 100%, 97% and 82% for stages I, IIA and IIB, respectively. Only B-symptoms independently predicted for inferior failure-free survival, while inferior overall survival was independently associated with the involvement of > or =3 sites. At 10 years failure-free survival was 82+/-6% (vs. 85+/-2% for patients with supradiaphragmatic disease, p=0.45), overall survival was 74+/-8% (vs. 91+/-2%, p=0.0006), and disease-specific survival 87+/-5% (vs. 94+/-1%, p=0.04). In multivariate analysis the differences between infradiaphragmatic and supradiaphragmatic disease were obscured by older age and B-symptoms. INTERPRETATION AND
CONCLUSIONS: Pure infradiaphragmatic HL presents with distinct clinicopathologic characteristics. The previously reported poorer outcome may be explained by the unfavorable profile of the patients rather than the infradiaphragmatic presentation per se. Patients with stage IIB disease should probably be classified as having advanced HL because of the unacceptable rate of primary refractory disease.

Entities:  

Mesh:

Year:  2006        PMID: 16434368

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  4 in total

1.  The role of primary lymph node sites in survival and mortality prediction in Hodgkin lymphoma: a SEER population-based retrospective study.

Authors:  Amr Ebied; Vuong Thanh Huan; Omar Mohamed Makram; To Kim Sang; Mohamed Ghorab; Huyen Thi Ngo; Ahmed Iraqi; Mohamed Gomaa Kamel; Tran Ngoc Dang; Nguyen Lam Vuong; Kenji Hirayama; Nguyen Tien Huy
Journal:  Cancer Med       Date:  2018-03-09       Impact factor: 4.452

2.  Beyond PET/CT in Hodgkin lymphoma: a comprehensive review of the role of imaging at initial presentation, during follow-up and for assessment of treatment-related complications.

Authors:  Abhishek R Keraliya; Sree Harsha Tirumani; Atul B Shinagare; Nikhil H Ramaiya
Journal:  Insights Imaging       Date:  2015-04-28

3.  Bulky Pelvic Hodgkin Lymphoma in a Prepubertal Girl.

Authors:  Sidharth Totadri; Deepak Bansal; Amanjit Bal; Prema Menon
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Apr-Jun

4.  Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT.

Authors:  Cédric Rossi; Morgane Mounier; Pauline Brice; Violaine Safar; Emmanuelle Nicolas-Virelizier; Philippe Rey; Aspasia Stamatoullas-Bastard; Marion Alcantara; Adrien Chauchet; Emilie Reboursière; Lauriane Filliatre; Aurore Perrot; Sylvain Garciaz; Gilles Salles; Bertrand Coiffier; Hervé Ghesquières; René-Olivier Casasnovas
Journal:  Oncotarget       Date:  2017-07-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.